Proximagen losses grow on R&D drive
This article was originally published in Scrip
Executive Summary
Proximagen Neuroscience's net loss grew during the first half of 2008 as its capacity was diverted away from revenue generating service contracts and towards progressing its preclinical programmes. Pretax losses rose by £520,000 to £1.6 million following modest increases in R&D costs and lower service contract revenue. R&D costs were £1.4 million (+33%) following clinical work on its PRX5 programme in Parkinson's disease, while service contracts bought in £200,000, a decrease of £300,000. The UK company's results beat analysts' expectations at Canaccord Adams, which reiterated its buy recommendation for the firm's stock.
You may also be interested in...
AB Science lists on Euronext after reducing offer size
AB Science has closed its IPO at just half of the value of its initial expectations. The gross proceeds of the French firm's offer were €27.5 million, compared with the €55.5 million it anticipated when it filed for the offering on 8 April. Of the total, the company secured $16.5 million from the sale of newly issued shares; the remaining €11 million went to selling shareholders.
Amgen posts strong first-quarter sales but healthcare reform set to bite
Amgen's sales rebounded in the first quarter rising 9% to $3.6 billion after a disappointing end to last year. However, the introduction of new legislation for US healthcare has weighed on its forecast for the year, as it has done for many of its competitors.
Tracleer drives growth for Actelion
Actelion's total revenues leapt up by 24% to CHF502 million ($467 million) during the first quarter due to stronger demand for its pharmaceuticals. The firm's net income rose by 30% to CHF133 million, while its diluted EPS increased from CHF0.83 in the first quarter last year to CHF1.09.